ImmuneOnco re-submitted a clinical trial application for the fusion protein drug IMM01 targeting CD47 to be accepted by NMPA
On March 20, 2019, ImmuneOnco re-submitted a clinical trial application for the fusion protein drug IMM01 targeting CD47 to be accepted by NMPA.
Previously on September 19, 2018, IMM01 submitted its first clinical trial application and was accepted by NMPA. Regarding the re-submission of IND, the founder of the company, Dr. Tian Wenzhi said, "The erythrocyte toxicity of CD47 has always attracted much attention, and NMPA has also conducted in-depth exchanges with us, especially with regard to new requirements for safety data. From a scientific point of view, we have done a lot of in vivo and in vitro experiments on the safety of CD47 targeted drugs, which proves once again that the molecules we designed have good safety to human red blood cells and platelets. On this basis, we resubmitted IND and accepted it smoothly. We are confident in the unique design and safety experiments of IMM01. We believe that IMM01 is expected to be a safe and effective best-in-class drug.”
The founder of the company, Dr. Tian Wenzhi, said that the safety of new drug research and development is the first consideration, so the patients'safety should always be the first consideration in the process of research and development. Therefore, comprehensive safety research must be done to ensure that the drug is "safe and effective". We firmly believe that the drugs we have developed are "safe and effective", so we sincerely hope that our drugs can be used in cancer patients as soon as possible.